Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run

Exelixis has delivered strong share-price gains in recent years, which puts fresh attention on a simple question for you as an investor. Is the current valuation supported by what the business is earning today and what those earnings suggest about the future? Over the past 3 years the stock has returned about 223.3%, so a lot of future earnings power is already being treated as meaningful by the market. The extended FDA review for zanzalintinib in metastatic colorectal cancer, now running to...